Short answer
The original patent that covered the rituximab antibody itself (U.S. Patent 5,739,269, “Human monoclonal antibody against CD20”) expired in 2009 (20 years from the 1989 filing date). Most other key patents that covered the drug’s formulation, use in specific diseases, and certain manufacturing processes expired in the early‑ to mid‑2010s. Roche still holds a handful of “process” and “method‑of‑treatment” patents that will expire in the mid‑2020s, but the biologic molecule itself is no longer under patent protection.
Because rituximab is a biologic, the U.S. and many other markets grant a 12‑year marketing exclusivity period in addition to the patent term. That exclusivity for the original product (Rituxan®) is set to lapse in 2026 in the United States. After that date, other manufacturers can market biosimilar versions (e.g., Truxima® from Janssen, which was approved in 2019) but cannot use the original brand name or the proprietary formulation.
---
What the patents covered
| Patent | Filing date | Expiry | What it covered |
|--------|-------------|--------|-----------------|
| US 5,739,269 (“Human monoclonal antibody against CD20”) | 1989-09-27 | 2009-09-27 | The rituximab antibody itself (structure, sequence, and general use). |
| US 6,416,030 (“Methods of treating lymphoma with rituximab”) | 1994-06-30 | 2014-06-30 | Use of rituximab in non‑Hodgkin’s lymphoma. |
| US 6,851,176 (“Rituximab formulations and methods of use”) | 1997-02-17 | 2017-02-17 | Formulations for intravenous infusion, dosing schedules. |
| US 7,112,539 (“Use of rituximab with other agents”) | 2005-12-12 | 2025-12-12 | Combination regimens with other chemotherapeutics. |
| US 8,102,317 (“Infusion rates and schedules”) | 2008-09-03 | 2028-09-03 | Optimized infusion rates to reduce reactions. |
| US 8,727,761 (“Manufacturing process for rituximab”) | 2009-07-31 | 2029-07-31 | Cell‑line development and purification steps. |
Note: The table lists only a subset of Roche’s patent portfolio. Many of the more specific “method‑of‑treatment” and “process” patents expire in the 2020s.
---
How this translates into commercial practice
| Timeline | What happens |
|----------|--------------|
| 1997 | Rituxan® (rituximab) receives FDA approval for non‑Hodgkin’s lymphoma. |
| 2009–2010 | Core antibody patent expires; Roche still holds many other patents. |
| 2017–2020 | Most formulation, use‑and‑combination patents expire; biosimilar market opens. |
| 2019 | Truxima® (biosimilar rituximab) is approved by the FDA, but only under a different brand name. |
| 2026 | U.S. 12‑year marketing exclusivity ends. Roche can still sell Rituxan®, but other biosimilars will be fully free to market. |
---
What you should keep in mind
| Issue | Detail |
|-------|--------|
| Biologic vs. small molecule | Patents for biologics cover the molecule, process, or method of use, but do not guarantee a product name or formulation. |
| Exclusivity vs. patent | Even after a patent expires, a drug can remain under regulatory exclusivity for 12 years. |
| Biosimilars | After exclusivity ends, competitors can launch biosimilars. These are highly similar to the reference product but not identical, and they must meet rigorous FDA standards for safety, purity, and efficacy. |
| International differences | Patent expiry dates and exclusivity periods